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Abstract 
Background: Schistosomiasis is a neglected tropical disease, targeted by the World Health Organization for reduc-
tion in morbidity by 2020. It is caused by parasitic flukes that spread through contamination of local water sources. 
Traditional control focuses on mass drug administration, which kills the majority of adult worms, targeted at school-
aged children. However, these drugs do not confer long-term protection and there are concerns over the emergence 
of drug resistance. The development of a vaccine against schistosomiasis opens the potential for control methods 
that could generate long-lasting population-level immunity if they are cost-effective.
Methods: Using an individual-based transmission model, matched to epidemiological data, we compared the 
cost-effectiveness of a range of vaccination programmes against mass drug administration, across three transmission 
settings. Health benefit was measured by calculating the heavy-intensity infection years averted by each interven-
tion, while vaccine costs were assessed against robust estimates for the costs of mass drug administration obtained 
from data. We also calculated a critical vaccination cost, a cost beyond which vaccination might not be economically 
favorable, by benchmarking the cost-effectiveness of potential vaccines against the cost-effectiveness of mass drug 
administration, and examined the effect of different vaccine protection durations.
Results: We found that sufficiently low-priced vaccines can be more cost-effective than traditional drugs in high 
prevalence settings, and can lead to a greater reduction in morbidity over shorter time-scales. MDA or vaccination 
programmes that target the whole community generate the most health benefits, but are generally less cost-effective 
than those targeting children, due to lower prevalence of schistosomiasis in adults.
Conclusions: The ultimate cost-effectiveness of vaccination will be highly dependent on multiple vaccine character-
istics, such as the efficacy, cost, safety and duration of protection, as well as the subset of population targeted for vac-
cination. However, our results indicate that if a vaccine could be developed with reasonable characteristics and for a 
sufficiently low cost, then vaccination programmes can be a highly cost-effective method of controlling schistosomia-
sis in high-transmission areas. The population-level immunity generated by vaccination will also inevitably improve 
the chances of interrupting transmission of the disease, which is the long-term epidemiological goal.
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Background
Schistosomiasis is estimated to affect over 250 million 
people, primarily in sub-Saharan Africa and South Amer-
ica. It is caused by water-borne parasitic flukes from the 
genus Schistosoma (predominantly Schistosoma mansoni, 
Schistosoma haematobium and Schistosoma japonicum), 
which enter the body through the skin and colonize the 
host’s bloodstream. Mated Schistosoma produce ferti-
lized eggs which stimulate an immune response, and 
this can lead to multiple pathologies including stunted 
growth, anemia, and in cases of severe burden, fibro-
sis of internal organs [1]. Eggs are passed into environ-
mental water systems through excreta, where they hatch 
and asexually multiply through intermediary snail hosts, 
completing their life-cycle.
Control in endemic regions is through mass drug 
administration (MDA), using the drug praziquantel [2]. 
Currently, MDA is implemented predominantly through 
school-based initiatives targeting school-aged chil-
dren (SAC), although in some areas community-wide 
programmes that also target adults are employed [3]. 
Substantial progress has been made recently in widen-
ing coverage, and schistosomiasis is on course to reach 
its WHO 2020 control target of treating 75% of SAC in 
endemic regions. Despite these advances, schistosomiasis 
is failing to meet the 2020 WHO control target of reduc-
ing heavy-intensity infections to below 5% prevalence in 
endemic regions [4]. Also, evidence demonstrating the 
ability of MDA to control the transmission of schistoso-
miasis in high prevalence areas is mixed, in part because 
the impact of MDA will vary across different epide-
miological settings. There are many regions, such as the 
Mekong River in Cambodia, where excellent progress 
has been made, with heavy-intensity infections reduced 
to below 1% [5, 6]. However, several recent studies in 
Africa have demonstrated limited progress in reducing 
prevalence in localized high-transmission areas, despite 
high MDA coverage [7–9]. Mathematical modelling sug-
gests that high coverage of both children and adults over 
sustained periods of time is required for MDA to control 
schistosomiasis in high-transmission areas, which may 
prove to be beyond practical limits [10, 11].
Vaccines against schistosomiasis are under develop-
ment, the most promising of which utilize the antigen 
protein Sm-p80. These vaccines are highly effective in 
baboon models: reducing the rate of establishment, 
fecundity and life-span of colonizing S. mansoni, par-
ticularly female worms [12–18]. The potential benefits 
for patients of an efficacious vaccine with lasting protec-
tion are clear; however, before investing in human trials, 
it is important to consider value-for-money in compari-
son to existing control methods. Studies conducted 20 
years previously, when an earlier generation of vaccine 
candidates were being investigated, used deterministic 
models to compare the effect of vaccination to MDA, and 
estimated the cost-effectiveness of vaccination but with-
out modelling the transmission [19, 20]. In this paper, we 
developed an individual-based model of schistosomia-
sis infection and control which accounts for population 
level heterogeneity and dynamical complexity. The model 
is used to investigate the cost-effectiveness of a potential 
vaccine across a range of plausible scenarios, varying the 
transmission setting, vaccine characteristics and delivery 
programmes. Also, by benchmarking the cost effective-
ness of vaccination programmes against the cost effec-
tiveness of current MDA programmes, we calculate a 
critical vaccination cost beyond which vaccination may 
not be economically favorable.
Methods
Transmission model
Our analysis uses a stochastic individual-based transmis-
sion model, where S. mansoni are explicitly transmitted 
between a population of human hosts and an external 
reservoir. This type of modelling for human helminth 
infections, first utilized by Anderson & Medley, means 
that considerable biological heterogeneity can be incor-
porated and allows for detailed examination of potential 
control strategies [21]. Since their inception, substantial 
improvements in computational power have allowed the 
use of individual-based models to efficiently sample their 
resulting distributions over time and overcome the inher-
ent noise in the dynamics. An alternative approach using 
deterministic compartment-based models, has been used 
to investigate the effects of vaccination, but this approach 
allows for less scope for including biological complexity 
[22, 23]. The transmission cycle, which is related to previ-
ously published models [11, 21, 24], is as follows:
• Mature adult schistosomes reproduce within human 
hosts monogamously. To account for within-host 
competition, fecundity (egg production per female 
schistosome) decays exponentially with the total 
number of mature schistosomes currently contained 
in the human host.
• Eggs are passed into an external reservoir, after which 
they hatch into larval stages. In the reservoir, the lar-
val stages have a fixed probability of dying each day. 
We do not model the snail component of the life-
cycle explicitly, because the dynamics of processes 
within the snails are fast in comparison to those 
within human hosts, so we may consider the density 
of larvae in the environment to a local equilibrium 
determined by the within human-population burden. 
Alternative models that include the snail component 
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have been used to investigate the effect of mollusci-
cides on the transmission [25, 26].
• Each day, human hosts come into contact with the 
reservoir and are infected. The average number of 
infecting larvae is proportional to the density of 
larvae in the reservoir, the individual’s risk-factor 
(assigned at birth from a gamma distribution) and 
a function of individual’s age. We assume that the 
population has generally poor access to sanitation, 
and hence the risk-factor and age only influence the 
uptake of larvae, not the deposition of eggs into the 
environment [27]. When a larval stage has infected a 
human host, it matures into an adult and is randomly 
assigned a sex.
Our model was parameterized with previously pub-
lished values and to match published epidemiological 
studies (see Table 1 and Additional file 1: Figure S1).
Prevalence measurement
For the implementation of control programmes, WHO 
guidelines require prevalence levels in the community 
to be monitored [3]. The Kato–Katz [28, 29] fecal smear 
test is the most widely used diagnostic test for S. man-
soni. Eggs are counted by eye from two samples to give 
an average number eggs per gram. Egg counts between 
0 and 4 indicate a low intensity infection, between 4 
and 16 indicate a moderate intensity infection, and 
greater than 16 indicate a heavy intensity infection 
[30]. We accounted for the over-dispersed nature of the 
recorded egg counts [31, 32] using a negative-binomial 
distribution. We stress that all results presented are in 
terms of this realized egg count, and not in terms of 
true worm-burden; this is important for vaccination 
which suppresses egg output, and because morbidity is 
most closely correlated with egg output.
Interventions: vaccination
The final characteristics of a human vaccine against 
schistosomiasis are as yet unknown, hence we used 
our mathematical model to consider the implications 
of different vaccine attributes (focusing on duration of 
protection) and different patterns of deployment. Immu-
nization of an individual is likely to be achieved with 
multiple vaccine doses spread across a number of weeks 
[14], dependent on vaccine characteristics and logistical 
factors. Given this uncertainty, we made the simplifying 
assumption that immunization occurs instantaneously at 
a specified time point. This assumption should have lim-
ited effect on results, because the period over which the 
vaccine is delivered is expected to be short compared to 
the duration of immunity.
On successful immunization, the vaccine is assumed to 
have two effects on the epidemiology of schistosomes: (i) 
a reduction of establishment of schistosomes in human 
hosts; and (ii) a reduction in fecundity of mature female 
schistosomes.
In keeping with recent trials of Sm-p80 vaccines in 
baboons, we made three key assumptions about the 
vaccine [14]. We assumed the vaccine does not have a 
therapeutic effect on already established schistosomes, 
i.e. there is no increase in the death rate. We modelled a 
partially efficacious vaccine that reduces establishment of 
new worms by 90% and reduces fecundity by 90%, which 
is comparable to the efficacy of a Sm-p80 vaccine in 
baboon model trials, although the duration of protection 
remains uncertain and is a key sensitivity in all our pre-
dictions. To cover a range of different potential vaccine 
protection durations, we generated results for vaccines 
with protection that lasts 2.5, 5, 10 and 20 years.
We modelled two types of vaccination programme: 
cohort delivery and delivery to larger groups. Cohort 
delivery is implemented by vaccinating children in par-
ticular age-groups annually. The age-groups chosen 
are based on the duration of vaccine protection, so that 
Table 1 Parameter values used in our individual-based transition model, and their sources
Parameter Value Reference
No. of human hosts in population, N 1000
Baseline prevalence in SAC High-transmission setting, 65%; Moderate-transmission setting, 45% (Obtained 
by scaling the contact rate between human hosts and the reservoir)
Age-dependent contact with reservoir Ages 0–4: 0.032; 5–9: 0.162; 10–14: 1.0; 15+: 0.05 [43]
Shape parameter α of Gamma distributed risk factor 0.24 [43]
Kato–Katz test aggregation parameter, k 0.87 [44, 45]
Exponential fecundity decay, z 0.0007/worm [23, 46]
Maximum fecundity, λ 0.14 egg counts/female worm [45, 47]
Average worm life-span 5.7 years [48]
Human demography Based on Kenya’s demographic profile [49]
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immunity is maintained up to age 15 (Table  2). Fur-
ther to this, we modelled the option of implementing a 
catch-up campaign in the first year of the programme to 
ensure than the whole target age-groups has protection 
from the first year of intervention. When modelling syn-
chronized delivery to larger groups, such as school-aged 
children (SAC) (with coverage the same as MDA), the 
vaccine is administered either once every two years or 
once every five years depending on the duration of vac-
cine protection.
Interventions: mass drug administration
The only drug widely available for preventative chemo-
therapy for schistosomiasis is praziquantel (PZQ), which 
is effective against all Schistosoma species [1]. WHO 
guidelines recommend a minimum coverage of at least 
75% of at-risk school-aged children [3]. However, in 
practice this level of coverage is not often attained [33], 
so our results are produced with three different cover-
age levels: (i) 40%; (ii) 60%; and (iii) 75%. Further to this, 
we included a scenario where community-based deliv-
ery is modelled, with a SAC coverage of 75% and adult 
coverage of 40%, which previous modelling suggests is a 
coverage level that is able to break transmission in a high-
prevalence setting [34]. PZQ is assumed to kill 86.3% of 
adult schistosomes within human hosts, but has no long-
lasting impact on either establishment or fecundity [35].
Systematic non-compliance, whereby individuals have 
a propensity to partake in MDA or not, can create a res-
ervoir of untreated hosts and will reduce the efficacy of 
MDA strategies. We modelled this using the methodol-
ogy of Dyson et al. [36], where the correlation of attend-
ance between rounds is controlled independently to the 
coverage. We used a correlation parameter ρ = 0.4 which 
is consistent with the range of correlations found for 
MDA within multiple studies (see references in [36]).
Cost and cost‑effectiveness analysis
Cost-effectiveness requires both a quantification of the 
health benefits of a given treatment programme as well 
as the associated economic costs. To measure the benefit 
of applying an intervention, we counted the total number 
of days that each individual has a heavy-intensity infec-
tion (HII), as measured by the Kato–Katz test [30] and 
recorded the total heavy-intensity infection years averted 
relative to the baseline of no intervention over a 30 year 
time horizon. Heavy-intensity infections have been cho-
sen as this accounts for the majority of negative health 
and societal effects (although we acknowledge significant 
schistosomiasis-related conditions such as anemia occur 
even for light-infections, and present alternative results 
where health benefits are measured in infection years 
averted in Additional file 1: Figures S2, S3) [37].
The cost efficacy of vaccination relative to MDA strat-
egies is critically dependent on the relative prices of 
vaccination and administering PZQ. One of the great 
benefits of MDA is that the drugs and delivery are rela-
tively cheap; the assumed costs of MDA are outlined in 
Table 3, using data from Additional file 1: Tables S1, S2. 
The costs for MDA delivery were assumed proportional 
to the number targeted for treatment (and not the num-
ber subsequently treated); while the cost for PZQ tablets 
was directly dependent on how many were treated.
The costs of the vaccination programme are unknown, 
so we performed two pieces of analysis. First, we 
Table 2 Schedule for cohort vaccination. Coverage for each age 
is 70%
Vaccine protection duration Cohort ages
2.5 years 1, 3, 5, 7, 9, 11, 13
5 years 1, 6, 11
10 years 1, 11
20 years 1
Table 3 Economic and financial costs for MDA delivery, obtained from online WHO regression tool [51] using median input values 
(see Table 4), and mean GDP per capita weighted by population needed to treat across endemic countries (see Additional file 1: 
Table S2)
Notes: Economic costs include costs associated with Ministry of Health buildings and time, as well as the value associated with volunteers’ time
a Includes US$0.08 per person for the opportunity costs related to the community volunteer who distribute the drugs which is not included with the WHO regression 
tool [52]
Cost Economic costs Financial costs Reference
School-based delivery Community-wide delivery School-based 
delivery
Community-wide 
delivery
Delivery cost (per person 
targeted)
US$0.75 US$0.50a US$0.31 US$0.34 [52]
PZQ tablets 2.5 × US$0.08 per child 2.5 × US$0.08 per child;
3.5 × US$0.08 per adult
Donated Donated [53, 54]
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considered three different immunization costs: US$3, 
US$6 and US$12 per full course of vaccine (not per dose 
and including delivery); this provides a more natural way 
of comparing vaccines that may require different number 
of doses. Secondly, we considered the critical vaccination 
cost, which is the cost of a course of vaccine that leads 
to the same cost-effectiveness as MDA (targeted at the 
appropriate equivalent section of the population). This 
can be considered to be a maximum price one would be 
willing to pay for vaccination, if cost is the only deciding 
factor.
Both analyses were performed under the health care 
providers perspective and quantify the cost-effectiveness 
of an intervention by the HII years averted per US$ spent 
over the course of the intervention. As recommended by 
the WHO, a discount rate of 3% per annum was applied 
to both the costs and effects [38].
Results
Comparison of interventions
Figure 1a shows the time-series of prevalence and heavy 
intensity infection prevalence in SAC (blue) and adults 
(orange) during 30-years of MDA targeted at SAC, start-
ing from a high-transmission baseline. The ‘bounce-back’ 
effect, where recently treated hosts are rapidly re-
infected, prevents large reductions in prevalence, despite 
years of repeated treatment.
We contrast this with a vaccine that provides protec-
tion for ten years, delivered to children in cohorts (at 
age 1 and 10 years); this generates a greater reduction 
in prevalence and heavy intensity prevalence in both 
SAC and adults than MDA (Fig. 1c). The reduction hap-
pens in two phases: (i) over the first ten year there is a 
reduction in SAC prevalence, due to increasing propor-
tions of immunized children; and (ii) after ten years the 
whole SAC class is protected, and subsequent reductions 
in prevalence due to a declining environmental reservoir 
are slower. The ultimate goal of interrupted transmission 
is not achieved within 30 years.
When a catch-up campaign is added in the first year 
of intervention (targeting individuals aged 1–15 years), 
prevalence and heavy-intensity infection prevalence are 
rapidly reduced (Fig. 1c), although there is a more limited 
impact on the longer-term prevalence (compare Fig.  1b 
and 1c). When SAC are vaccinated once every 5-years 
(Fig.  1d) there is a notable bounce-back after interven-
tion, as unvaccinated pre-SAC children mature into the 
SAC group, but this is much slower than the bounce-back 
seen after a round of MDA. The long-term prevalence is 
comparable to that seen in the cohort strategies.
Broader interventions that target the community 
are able to give faster and greater reductions in preva-
lence (Fig.  2). After 20-years of community-wide MDA 
treatment (75% SAC, 40% adult coverage), heavy-inten-
sity infections are effectively eliminated, and within 
30 years interruption of transmission is also possible 
(Fig.  2a). When vaccination is delivered at the whole-
community level (again vaccinating 75% SAC and 40% 
adults), the speed of eradication is faster still, i.e. eradi-
cating heavy intensity infection after 15 years.
Cost‑effectiveness: high‑transmission setting
Figure  3 shows the cost-efficacy of each intervention; 
columns correspond to differing vaccine durations, rows 
to differing assumed vaccination costs (US$3, US$6 and 
US$12 per full course of vaccine including delivery). Each 
point corresponds to a different strategy and reflects the 
benefits of the programme (x-axis) against the economic 
costs (y-axis). Strategies to the right (more effective) 
and below (cheaper) are more cost-effective than those 
to the left and above. Grey lines link points with equal 
cost-effectiveness.
Due to the economies of scale, MDA becomes more 
cost-effective as coverage increases (red circles for cov-
erages of 40%, 60% and 75% of school-aged children 
(SAC)). Extending MDA to the whole community (red 
pentagon) provides much more benefit than SAC MDA, 
but is less cost-effective; thus while community MDA 
offers a greater reduction in heavy-infections it comes at 
a relatively higher cost; a greater reduction would be to 
distribute the same amount of PZQ to school-aged chil-
dren in more communities.
Somewhat counter intuitively, the simple cohort-vac-
cination programme (blue cross) has the greatest health 
benefit when the vaccine only offers a short duration 
of protection; this is because, more age-groups have 
to be vaccinated annually hence protection of all SAC 
is reached earlier; however, this leads to a much higher 
cost associated with the programme. For a similar reason 
including a catch-up campaign is of greater benefit for 
vaccines with longer protection, although catch-up cam-
paigns are always less cost-effective than the underlying 
cohort-vaccination (comparing blue and orange crosses). 
Community vaccination (purple symbols) is associated 
with high costs, but has the potential to achieve elimi-
nation if the vaccine confers sufficiently long immu-
nity. The high costs are partly offset by interruption of 
transmission (meaning that no further vaccinations are 
administered from that point onwards), but such gains 
are limited due to discounting in predicted costs and 
benefits over long time periods. For vaccines that confer 
less than 20-years protection, immunizing SAC every 5 
years (green square) is the most cost-effective vaccine-
based strategy, while immunizing children in cohorts 
together with a catch-up campaign (orange cross) is the 
most cost-effective vaccine strategy if protection lasts for 
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Fig. 1 High-transmission setting: prevalence (left) and heavy intensity infection prevalence (right) in SAC and adults during 30 years of control. 
Shaded regions represent the 95% prediction interval (i.e. 95% of all stochastic simulations lie within this region). a MDA targeted at SAC with 75% 
coverage. b Cohort vaccination (at 1- and 10 years-old). c Cohort vaccination (at 1- and 10 years-old) and a catch-up campaign in the first year. d 
Mass SAC vaccination, every 5 years. In all cases the vaccine is assumed to offer 10 years protection
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20 years. When comparing the cost effectiveness of vac-
cination against MDA, the cost of delivering a full course 
of the vaccine is obviously a key consideration. When 
the costs are just US$3.0 for immunization (top row of 
Fig. 3), vaccination can be more cost-effective than MDA, 
depending on choosing the best deployment strategy. 
As vaccination costs increase, the most cost-effective 
method becomes dependent on the assumed duration 
of protection. However, when the costs are US$12.0 per 
course of vaccine, MDA targeted at SAC (with at least 
75% coverage) is always the most cost-effective interven-
tion regardless of vaccine protection duration.
Rather than considering a limited number of vaccina-
tion costs, we now calculate a critical vaccination cost 
(defined as the cost, per course of vaccine, that achieves 
the same cost-effectiveness as MDA targeted at the rel-
evant section of the community) for each vaccination 
strategy, and for each vaccine duration of protection 
(Fig.  4). These critical vaccination costs provide a rapid 
assessment of the maximal price for vaccination to be 
preferable to MDA, all other aspects being equal.
For a 2.5-year-duration vaccine, our predictions sug-
gest that costs for vaccination greater than US$3.0 per 
vaccination are not cost-effective, regardless of strategy. 
However, as the duration of protection increases, so 
does the critical vaccination cost. For 5- and 10-year vac-
cines, vaccinating SAC every 5 years provides the most 
cost-efficacy with a critical vaccination cost of US$6.5 
and US$7.4 per vaccination course, while for vaccines 
that give 20 years of protection, the cohort based strate-
gies provide the greatest cost-efficacy, leading to a critical 
vaccination cost of US$8 per vaccination course. Hence, 
the vaccine must be able to provide long-duration pro-
tection and be less than $8 per course for it to be more 
cost-effective than current MDA control measures. We 
note that while community-wide vaccination provides 
Fig. 2 High-transmission setting: prevalence (left) and heavy intensity infection prevalence (right) in SAC and adults during 30 years of control. a 
MDA targeted at the whole community (75% SAC coverage, 40% adult coverage). b Vaccination every 5 years, with a vaccine that offers 10 years 
protection, targeted at the community (75% SAC coverage, 40% adult coverage)
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the most health benefits, the vaccination of adults pro-
vides less efficacy as adults generally have less contact 
with the infectious reservoir.
Cost‑effectiveness: moderate‑transmission setting
In Figs. 5 and 6 we repeated our analysis in a moderate-
transmission setting (with a baseline SAC prevalence 
of 45%). In general, lower baseline prevalence leads to 
MDA being relatively more cost-effective compared to 
Fig. 3 High-transmission setting: incremental cost-effectiveness diagrams across differing vaccine protection lengths (columns) and relative 
vaccination costs (rows), for MDA and vaccination-based strategies (points). Radial gridlines (grey) indicate equal cost-efficacy (i.e. the same number 
of heavy-intensity infection years averted per dollar). The cost per vaccination represents the full course of vaccine (not per dose and including 
delivery)
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vaccination, as the reinfection after chemotherapy is 
slower (Fig. 5). Many strategies now provide similar lev-
els of reduction of heavy-intensity infections, and so 
cost-effectiveness is determined purely by the cost of the 
strategy. Only when the vaccination is extremely cheap 
(US$3 per course) and protection is long-lasting can it be 
more cost-effective than MDA. As expected, the critical 
vaccination cost in the moderate-transmission setting are 
consistently lower than in the high-transmission setting 
(Fig.  6). Our modelling indicates that one should only 
be willing to pay up-to US$3.7 per vaccination course, 
should cost be the only deciding factor in choosing 
between MDA and vaccination.
Discussion
We have developed a predictive individual-based model 
of schistosomiasis dynamics that can account for the 
action of both traditional drug treatment and control by 
vaccines currently under development; this allowed us to 
assess both the epidemiological impact and associated 
cost of different control strategies. The model has been 
matched to data from a variety of epidemiological stud-
ies and mechanistically captures the individual-levels 
dynamics of humans and schistosomes; however, there 
are a number of facets where additional data could help 
to refine the model assumptions, as discussed below.
Our model neglects the possible role of acquired 
immunity that may be caused by prolonged exposure to 
schistosomes [39]. This could potentially reduce the ben-
efits of a vaccine, as older individuals would already be 
experiencing some level of immunity. Acquired immunity 
for schistosomiasis is not well understood, partly due to 
the difficulty in disentangling its effect from age-related 
exposure, and further research in this area is needed.
Due to the limited understanding of the causal link 
between schistosomiasis morbidity and burden, caution 
should be employed when interpreting modelling results 
regarding the amount of schistosomiasis morbidity 
averted by different interventions [37]. In principle, the 
disability-adjusted life year (DALY) averted would be an 
ideal metric to use, but further research is needed in this 
area to make this possible [37].
There are also limited cost data on MDA particularly 
regarding the relative cost of school vs community-based 
treatment (and therefore the results regarding the rela-
tive cost-effectiveness of these interventions should be 
treated with caution). There is an important research 
need for improving the economic evaluations of different 
schistosomiasis interventions.
Finally, our modelling does not include the effect of 
improvements to water, sanitation and hygiene (often 
referred to as WASH) that may be expected over the 
course of a control programme. Including these effects 
into the modelling relies on the availability of quantita-
tive data that measure both exposure and contribution to 
the infective reservoir, and at present time this longitudi-
nal data have proved challenging to collect.
The development of a vaccine through the stages of 
clinical trials will require substantial resources, and the 
challenge of developing a successful vaccine against a 
macroparasite should not be underestimated; efforts 
to find a vaccine for schistosomiasis have been ongoing 
since the 1990s [40]. The production of a licensed vaccine 
is at a minimum ten years away, so the need for a vaccine 
Fig. 4 High-transmission setting: critical vaccination costs (comprising delivery and vaccine costs), relative to MDA, for school and community-wide 
strategies. Critical vaccination cost is defined by the cost, per course of vaccine, that achieves the same cost-effectiveness as MDA targeted at the 
relevant section of the community
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is contingent on the amount of progress being made dur-
ing that time period. The global trend of increased cov-
erage for preventative chemotherapy is encouraging. As 
progress continues, the analysis presented in this study 
should be repeated with models fit to longitudinal data 
that accurately represent the situations where a vaccine 
would be used. This may include scenarios where vacci-
nation follows MDA, or MDA and vaccination are used 
in combination. The impact of such an approach is likely 
to be sensitive to the initial period of MDA, whether 
Fig. 5 Moderate-transmission setting incremental cost-effectiveness diagrams across differing vaccine protection lengths (columns) and relative 
vaccination costs (rows), for MDA and vaccination based strategies. Radial gridlines indicate locations on the plane of equal cost-efficacy. The cost 
per vaccination represents the full course of vaccine (not per dose and including delivery)
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vaccination is used singly or in combination, as well as 
the unknown characteristics of the vaccine. Such a multi-
dimensional exploration of parameter space is beyond 
the scope of this paper, and would be best to be consid-
ered on a case-by-case basis. It should be noted that vac-
cination in high-transmission areas where prevalence has 
been suppressed by MDA is not directly comparable to 
vaccination in un-controlled low and moderate trans-
mission settings, even if the prevalence levels are similar. 
Current evidence suggests that in high-transmission set-
tings, where the vaccine is most cost-effective, infection 
may still persist at relatively high levels in ten years’ time 
even when MDA is applied.
In high transmission settings, we estimated a criti-
cal vaccination costs of approximately US$8 per vaccine 
course if long-duration protection is generated; at this 
price vaccination and MDA are equally cost-effective. 
This generates an upper bound on the potential willing-
ness to pay for the vaccine. However, and most impor-
tantly, these do not necessarily reflect a realistic or 
achievable market price for a schistosomiasis vaccine. 
To put these costs into context, one can take the recent 
example of vaccines targeted against Human Papilloma-
virus (HPV), Gardasil and Cervarix, which are produced 
by Merck and GSK respectively. In 2018 the median price 
of Gardasil-4 and Cervarix-2 for Gavi-supported coun-
tries was US$4.55 per dose. For non-Gavi middle-income 
countries median prices were approximately US$16 per 
dose, while in high-income countries the prices for Gar-
dasil-4 and Cervarix-2 were $26 and $38 per dose [41]. 
Note that Gardasil requires a 2-dose schedule, while Cer-
varix requires a 3-dose schedule, further increasing the 
costs, in addition to the costs associated with delivery 
must also be factored into the calculation. Furthermore, 
unlike for HPV, there is no market for a schistosomiasis 
vaccine in high-income countries. The example of HPV 
would suggest that a significant subsidy is necessary for 
a vaccine to be produced at a price low enough for the 
countries which harbour the heaviest schistosomiasis 
burden to (i) afford to be able to purchase and deliver the 
quantities required; and (ii) be as cost-effective as MDA 
campaigns with high coverage.
Importantly, it should be noted that the results gener-
ated in this study are for a hypothetical vaccine with a 
mode of action and efficacy that resembles that of the 
Sm-p80 vaccine in baboon experiments, and that further 
analysis should be conducted if a vaccine is developed 
to the point where efficacy and safety in humans can be 
measured.
Conclusions
Given that an estimated 243 million people live in high-
risk areas for schistosomiasis, there is a strong need for 
cheap and effective methods to reduce the burden and 
associated morbidity [42]. Our cost-effectiveness com-
parisons of MDA and vaccination are highly dependent 
on the transmission setting, the duration of vaccine pro-
tection and the cost of the vaccine. They are also depend-
ent on the efficacy of the vaccine in humans being similar 
to the efficacy found in baboon trials. In high-transmis-
sion settings, we found that all treatments (both MDA 
and vaccine) have a substantial impact on schistosomia-
sis, significantly reducing the prevalence of high worm 
burdens. In general, well-targeted vaccination campaigns 
Fig. 6 Moderate-transmission setting: critical vaccination costs (comprising delivery and vaccine costs), relative to MDA, for school and 
community-wide strategies. Critical vaccination cost is defined by the cost, per course of vaccine, that achieves the same cost-effectiveness as MDA 
targeted at the relevant section of the community
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produce a greater reduction in heavy-intensity infec-
tions than MDA, although the cost-effectiveness is highly 
sensitive to the duration of protection generated by the 
vaccine, the cost of each dose and the transmission set-
ting, i.e. long protection, low cost and high transmis-
sion all make vaccines more cost-effective. Our results 
therefore provide key characteristics for when vaccina-
tion is more cost effective than current MDA strategies. 
Under the most favorable conditions examined (high 
transmission setting, 20 years of protective immunity 
and an optimal deployment strategy) vaccination offers 
substantial health benefits over school-aged MDA but is 
only more cost-effective than MDA if immunization can 
be achieved for less than US$8. Vaccines offering shorter 
immunity are less cost-effective although they can still 
generate substantial health benefits; while in lower-trans-
mission settings the cost-effectiveness of vaccination rel-
ative to MDA is further reduced. Two additional factors, 
beyond cost effectiveness, may influence the decision to 
adopt vaccination as a control method. The first is the 
greater reductions in heavy intensity infections that can 
be achieved by vaccination. The second is concerns about 
the potential emergence and spread of drug resistance to 
praziquantel, in which case vaccination offers an alterna-
tive method of control.
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